Assenagon Asset Management S.A.
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1546007
SENNINGERBERG, N4
Position in ELVN
as of Jun 30, 2026
· filed Aug 21, 2026
Position Value
$15,558,630
New position
Shares Held
306,574
first reported quarter
Ownership
0.418%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#54
of 210 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Assenagon Asset Management S.A. holds $1,940,218,245 across 69 Biotechnology names. ELVN ranks #27 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
759,564 | $377,298,225 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
8,362,952 | $295,964,871 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
244,927 | $152,721,781 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
454,682 | $111,292,513 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
1,762,086 | $100,826,560 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
997,643 | $78,085,517 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
124,214 | $66,696,707 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
947,495 | $59,635,335 |
All Filings in ELVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,558,630 | 306,574 | Shares | Sole | 2026-08-21 | |
| No filing history on record for this holder in this stock. | ||||||